Saudi Arabia

Saudi Arabia

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
2.72 (2.31 - 3.14) 2019 Modelled IHME
2.92 (2.53 - 3.28) 2018 Modelled IHME
3.01 (2.58 - 3.38) 2017 Modelled IHME
2.99 (2.62 - 3.34) 2016 Modelled IHME
2.96 (2.58 - 3.37) 2015 Modelled IHME
3 (2.63 - 3.39) 2014 Modelled IHME
3.08 (2.71 - 3.47) 2013 Modelled IHME
3.19 (2.81 - 3.58) 2012 Modelled IHME
3.3 (2.91 - 3.71) 2011 Modelled IHME
3.4 (2.99 - 3.84) 2010 Modelled IHME
3.48 (3.08 - 3.91) 2009 Modelled IHME
3.56 (3.16 - 3.99) 2008 Modelled IHME
3.64 (3.23 - 4.06) 2007 Modelled IHME
3.72 (3.31 - 4.15) 2006 Modelled IHME
3.81 (3.38 - 4.28) 2005 Modelled IHME
3.92 (3.50 - 4.37) 2004 Modelled IHME
4.04 (3.62 - 4.48) 2003 Modelled IHME
4.17 (3.76 - 4.61) 2002 Modelled IHME
4.31 (3.89 - 4.78) 2001 Modelled IHME
4.47 (4.03 - 4.96) 2000 Modelled IHME
4.65 (4.22 - 5.11) 1999 Modelled IHME
4.84 (4.42 - 5.30) 1998 Modelled IHME
5.06 (4.63 - 5.52) 1997 Modelled IHME
5.31 (4.85 - 5.77) 1996 Modelled IHME
5.57 (5.08 - 6.09) 1995 Modelled IHME
5.88 (5.37 - 6.35) 1994 Modelled IHME
6.23 (5.71 - 6.71) 1993 Modelled IHME
6.61 (6.03 - 7.12) 1992 Modelled IHME
7.04 (6.39 - 7.59) 1991 Modelled IHME
7.49 (6.77 - 8.08) 1990 Modelled IHME
2.05 (1.65 - 2.51) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.15 (0.12 - 0.19) 2019 Modelled IHME
0.16 (0.12 - 0.20) 2018 Modelled IHME
0.16 (0.13 - 0.21) 2017 Modelled IHME
0.16 (0.13 - 0.20) 2016 Modelled IHME
0.16 (0.13 - 0.21) 2015 Modelled IHME
0.16 (0.13 - 0.21) 2014 Modelled IHME
0.17 (0.14 - 0.21) 2013 Modelled IHME
0.17 (0.14 - 0.22) 2012 Modelled IHME
0.18 (0.15 - 0.23) 2011 Modelled IHME
0.19 (0.15 - 0.24) 2010 Modelled IHME
0.2 (0.17 - 0.25) 2009 Modelled IHME
0.22 (0.18 - 0.27) 2008 Modelled IHME
0.24 (0.19 - 0.30) 2007 Modelled IHME
0.26 (0.21 - 0.32) 2006 Modelled IHME
0.28 (0.22 - 0.35) 2005 Modelled IHME
0.3 (0.24 - 0.37) 2004 Modelled IHME
0.31 (0.26 - 0.40) 2003 Modelled IHME
0.34 (0.28 - 0.42) 2002 Modelled IHME
0.36 (0.30 - 0.44) 2001 Modelled IHME
0.38 (0.32 - 0.48) 2000 Modelled IHME
0.41 (0.34 - 0.51) 1999 Modelled IHME
0.44 (0.37 - 0.54) 1998 Modelled IHME
0.47 (0.39 - 0.57) 1997 Modelled IHME
0.51 (0.43 - 0.62) 1996 Modelled IHME
0.57 (0.47 - 0.69) 1995 Modelled IHME
0.67 (0.56 - 0.82) 1994 Modelled IHME
0.85 (0.71 - 1.03) 1993 Modelled IHME
1.08 (0.90 - 1.30) 1992 Modelled IHME
1.36 (1.11 - 1.62) 1991 Modelled IHME
1.66 (1.35 - 1.99) 1990 Modelled IHME
0.3 (0.20 - 0.44) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
39 (30 - 49) 2019 Modelled IHME
39 (30 - 49) 2018 Modelled IHME
38 (30 - 49) 2017 Modelled IHME
38 (29 - 48) 2016 Modelled IHME
38 (29 - 48) 2015 Modelled IHME
38 (29 - 47) 2014 Modelled IHME
37 (29 - 47) 2013 Modelled IHME
37 (29 - 47) 2012 Modelled IHME
37 (28 - 47) 2011 Modelled IHME
37 (28 - 47) 2010 Modelled IHME
37 (28 - 47) 2009 Modelled IHME
37 (29 - 47) 2008 Modelled IHME
38 (29 - 48) 2007 Modelled IHME
38 (30 - 48) 2006 Modelled IHME
38 (30 - 48) 2005 Modelled IHME
38 (30 - 48) 2004 Modelled IHME
38 (30 - 48) 2003 Modelled IHME
38 (30 - 48) 2002 Modelled IHME
39 (30 - 49) 2001 Modelled IHME
39 (31 - 49) 2000 Modelled IHME
40 (31 - 50) 1999 Modelled IHME
41 (32 - 51) 1998 Modelled IHME
42 (33 - 52) 1997 Modelled IHME
43 (34 - 53) 1996 Modelled IHME
43 (34 - 53) 1995 Modelled IHME
43 (34 - 53) 1994 Modelled IHME
43 (34 - 53) 1993 Modelled IHME
43 (34 - 53) 1992 Modelled IHME
43 (34 - 52) 1991 Modelled IHME
42 (34 - 52) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
98 2018 Survey/reported WHO/UNICEF
96 2017 Survey/reported WHO/UNICEF
98 2016 Survey/reported WHO/UNICEF
98 2015 Survey/reported WHO/UNICEF
98 2014 Survey/reported WHO/UNICEF
99 2013 Survey/reported WHO/UNICEF
99 2012 Survey/reported WHO/UNICEF
98 2011 Survey/reported WHO/UNICEF
98 2010 Survey/reported WHO/UNICEF
98 2009 Survey/reported WHO/UNICEF
98 2008 Survey/reported WHO/UNICEF
96 2007 Survey/reported WHO/UNICEF
95 2006 Survey/reported WHO/UNICEF
96 2005 Survey/reported WHO/UNICEF
95 2004 Survey/reported WHO/UNICEF
94 2003 Survey/reported WHO/UNICEF
98 2002 Survey/reported WHO/UNICEF
94 2001 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
97 2018 Survey/reported WHO/UNICEF
98 2017 Survey/reported WHO/UNICEF
98 2016 Survey/reported WHO/UNICEF
98 2015 Survey/reported WHO/UNICEF
98 2014 Survey/reported WHO/UNICEF
98 2013 Survey/reported WHO/UNICEF
98 2012 Survey/reported WHO/UNICEF
98 2011 Survey/reported WHO/UNICEF
98 2010 Survey/reported WHO/UNICEF
98 2009 Survey/reported WHO/UNICEF
98 2008 Survey/reported WHO/UNICEF
96 2007 Survey/reported WHO/UNICEF
96 2006 Survey/reported WHO/UNICEF
97 2005 Survey/reported WHO/UNICEF
96 2004 Survey/reported WHO/UNICEF
95 2003 Survey/reported WHO/UNICEF
97 2002 Survey/reported WHO/UNICEF
95 2001 Survey/reported WHO/UNICEF
93 2000 Survey/reported WHO/UNICEF
92 1999 Survey/reported WHO/UNICEF
95 1998 Survey/reported WHO/UNICEF
91 1997 Survey/reported WHO/UNICEF
92 1996 Survey/reported WHO/UNICEF
93 1995 Survey/reported WHO/UNICEF
94 1994 Survey/reported WHO/UNICEF
93 1993 Survey/reported WHO/UNICEF
89 1992 Survey/reported WHO/UNICEF
86 1991 Survey/reported WHO/UNICEF
66 1990 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1995
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
3.28 (2.65 - 4.09) 2019 Modelled IHME
3.25 (2.62 - 4.06) 2018 Modelled IHME
3.23 (2.59 - 4.07) 2017 Modelled IHME
3.19 (2.58 - 3.98) 2016 Modelled IHME
3.16 (2.55 - 3.98) 2015 Modelled IHME
3.17 (2.56 - 3.99) 2014 Modelled IHME
3.2 (2.58 - 4.02) 2013 Modelled IHME
3.23 (2.60 - 4.05) 2012 Modelled IHME
3.25 (2.61 - 4.07) 2011 Modelled IHME
3.27 (2.62 - 4.07) 2010 Modelled IHME
3.25 (2.63 - 4.07) 2009 Modelled IHME
3.21 (2.61 - 4.04) 2008 Modelled IHME
3.15 (2.56 - 3.93) 2007 Modelled IHME
3.09 (2.50 - 3.85) 2006 Modelled IHME
3.02 (2.44 - 3.78) 2005 Modelled IHME
2.92 (2.38 - 3.65) 2004 Modelled IHME
2.78 (2.28 - 3.44) 2003 Modelled IHME
2.64 (2.16 - 3.23) 2002 Modelled IHME
2.53 (2.07 - 3.08) 2001 Modelled IHME
2.49 (2.03 - 3.03) 2000 Modelled IHME
2.5 (2.04 - 3.05) 1999 Modelled IHME
2.54 (2.06 - 3.09) 1998 Modelled IHME
2.59 (2.11 - 3.16) 1997 Modelled IHME
2.65 (2.16 - 3.25) 1996 Modelled IHME
2.72 (2.22 - 3.40) 1995 Modelled IHME
2.82 (2.29 - 3.50) 1994 Modelled IHME
2.96 (2.40 - 3.65) 1993 Modelled IHME
3.13 (2.52 - 3.88) 1992 Modelled IHME
3.33 (2.67 - 4.11) 1991 Modelled IHME
3.54 (2.82 - 4.38) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
1.5 (0.60 - 7.30) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
77.8 (73.20 - 81.90) 2012 Survey/reported Alshomrani AT, 2015

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
34 (24 - 43) 2019 Modelled IHME
34 (24 - 43) 2018 Modelled IHME
34 (24 - 44) 2017 Modelled IHME
35 (25 - 44) 2016 Modelled IHME
35 (25 - 44) 2015 Modelled IHME
35 (26 - 44) 2014 Modelled IHME
36 (26 - 45) 2013 Modelled IHME
36 (27 - 45) 2012 Modelled IHME
36 (27 - 45) 2011 Modelled IHME
36 (27 - 45) 2010 Modelled IHME
36 (27 - 45) 2009 Modelled IHME
36 (27 - 45) 2008 Modelled IHME
36 (26 - 45) 2007 Modelled IHME
36 (26 - 45) 2006 Modelled IHME
36 (26 - 45) 2005 Modelled IHME
36 (26 - 45) 2004 Modelled IHME
36 (26 - 45) 2003 Modelled IHME
36 (26 - 45) 2002 Modelled IHME
36 (26 - 45) 2001 Modelled IHME
35 (26 - 44) 2000 Modelled IHME
35 (25 - 44) 1999 Modelled IHME
34 (25 - 43) 1998 Modelled IHME
34 (25 - 43) 1997 Modelled IHME
33 (25 - 42) 1996 Modelled IHME
33 (24 - 42) 1995 Modelled IHME
33 (24 - 42) 1994 Modelled IHME
33 (24 - 42) 1993 Modelled IHME
34 (25 - 42) 1992 Modelled IHME
34 (25 - 42) 1991 Modelled IHME
34 (25 - 43) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1995
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
2.72 (%)
2019
(2.31 - 3.14(%))
IHME
HCV (RNA/cAg+)
3.28 (%)
2019
(2.65 - 4.09(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
784
2019
(570 - 1,055)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
2,362
2019
(1,763 - 2,975)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.15 (%)
2019, latest modelled
(0.12 - 0.19(%))
IHME

Prevalence PWID

HCV
77.80 (%)
2012, survey/surveillance
(73.20 - 81.90(%))
Alshomrani AT, 2015

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
98 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines